Seneca Biopharma (NASDAQ:SNCA) spotted trading -93.97% off 52-week high price. On the other end, the stock has been noted 40.00% away from the low price over the last 52-weeks. The stock changed 14.87% to recent value of $0.7. The stock transacted 1206227 shares during most recent day however it has an average volume of 1.86M shares. The company has 8.25M of outstanding shares and 7.93M shares were floated in the market.
On April 3, 2020, Seneca Biopharma (NASDAQ:SNCA) a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, reported the completion of its new cell manufacturing facility in Suzhou, China. The facility will be used to manufacture NSI-566, the company’s lead stem cell therapy, for clinical trials within China, including a non-GCP compliant Phase II trial currently underway for the treatment of chronic ischemic stroke at the BaYi Brain Hospital in Beijing. Stroke is the leading cause of death and disability in China.
Completion of our new facility in Suzhou is a key milestone in Seneca’s product development strategy, said Dr. Ken Carter, Executive Chairman of Seneca. This facility will allow us to manufacture cells to support our current and future clinical trials in China. Further, Dr. Carter commented I’d like to personally thank the staff who have been able to move forward on this plan while maintaining their safety during these uncertain times.
About Seneca Biopharma
Seneca Biopharma, is a clinical-stage biopharmaceutical company developing novel treatments for diseases of high unmet medical need. The Company is in the process of transforming the organization through the acquisition or in-licensing of new science and technologies, to develop with the goal of providing meaningful therapies for patients.
According to the most recent quarter its current ratio was 4.6 that represents company’s ability to meet its current financial obligations. The price moved ahead of 7.28% from the mean of 20 days, -19.49% from mean of 50 days SMA and performed -63.22% from mean of 200 days price. Company’s performance for the week was 11.15%, -17.48% for month and YTD performance remained -29.29%.